Cargando…
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes
INTRODUCTION: Gene expression analysis is used to subtype breast cancers such that the most aggressive tumors are identified, but translating this into clinical practice can be cumbersome. Our goal is to develop a universal biomarker that distinguishes patients at high risk across all breast cancer...
Autores principales: | Habibi, Golareh, Leung, Samuel, Law, Jennifer H, Gelmon, Karen, Masoudi, Hamid, Turbin, Dmitry, Pollak, Michael, Nielsen, Torsten O, Huntsman, David, Dunn, Sandra E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614522/ https://www.ncbi.nlm.nih.gov/pubmed/18925950 http://dx.doi.org/10.1186/bcr2156 |
Ejemplares similares
-
Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1
por: Kalra, J, et al.
Publicado: (2010) -
Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis
por: Turashvili, Gulisa, et al.
Publicado: (2009) -
Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases
por: Rajput, Ashish B., et al.
Publicado: (2007) -
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy
por: Stratford, Anna L, et al.
Publicado: (2007) -
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
por: Fernand ez-Martinez, Aranzazu, et al.
Publicado: (2017)